Maturation of Cardiomyocytes Derived from Human Pluripotent Stem Cells: Current Strategies and Limitations
Yanqing Jiang1,5, Peter Park2,5, Sang-Min Hong3, and Kiwon Ban4,*
1University of Toronto, Hospital of Sick Children, Toronto, Canada, 2Emory University, Department of Biology, Atlanta, Georgia, USA, 3Department of Physical Education, Dongguk University Seoul, Seoul 04620, Korea, 4Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, 5These authors contributed equally to this work.
Received March 6, 2018; Revised May 9, 2018; Accepted May 10, 2018.; Published online June 12, 2018.
© Korean Society for Molecular and Cellular Biology. All rights reserved.

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License. To view a copy of this license, visit (
The capacity of differentiation of human pluripotent stem cells (hPSCs), which include both embryonic stem cells and induced pluripotent stem cells, into cardiomyocytes (CMs) in vitro provides an unlimited resource for human CMs for a wide range of applications such as cell based cardiac repair, cardiac drug toxicology screening, and human cardiac disease modeling. However, their applicability is significantly limited by immature phenotypes. It has been well known that currently available CMs derived from hPSCs (hPSC-CMs) represent immature embryonic or fetal stage CMs and are functionally and structurally different from mature human CMs. To overcome this critical issue, several new approaches aiming to generate more mature hPSC-CMs have been developed. This review describes recent approaches to generate more mature hPSC-CMs including their scientific principles, advantages, and limitations.
Keywords: cardiomyocytes, human pluripotent stem cells, immaturity, maturation

Current Issue

30 June 2018 Volume 41,
Number 6, pp. 495~611

This Article

Cited By Articles
  • CrossRef (0)

Social Network Service

Indexed in

  • Science Central
  • CrossMark